Decline in breast cancer incidence due to removal of promoter: Combination estrogen plus progestin

Breast Cancer Research

Volumn 9, Issue 4, 2007, Pages

  Colditz, Graham A ^a  

^a USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; GESTAGEN; TUMOR PROMOTER;

BREAST CANCER; CANCER INCIDENCE; CANCER RISK; DRUG POTENTIATION; DRUG SAFETY; DRUG USE; EDITORIAL; HORMONAL THERAPY; HUMAN; OBESITY; PREVALENCE; RISK FACTOR; RISK REDUCTION; TREATMENT WITHDRAWAL; BREAST TUMOR; DRUG COMBINATION; ESTROGEN THERAPY; FEMALE; NOTE;

BREAST NEOPLASMS; DRUG THERAPY, COMBINATION; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; PROGESTINS;

EID: 36749006647     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr1736     Document Type: Editorial

References (22)

1. Jemal A Ward E Thun MJ Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Breast Cancer Res 2007, 9:R28. 1929089 17477859 10.1186/bcr1672
2. International Agency for Research on Cancer Combined estrogen-progestogen postmenopausal therapy Combined Estrogen-progestogen Contraceptives and Combined Estrogen-progestogen Menopausal Therapy Lyon: International Agency for Research on Cancer 2007 91 http://monographs.iarc.fr/ENG/Meetings/91-menop-ther.pdf
3. Austin DF Roe KM The decreasing incidence of endometrial cancer: Public health implications Am J Public Health 1982, 72:65-68. 1649756 7053625
4. Colditz GA Hankinson SE Hunter DJ Willett WC Manson JE Stampfer MJ Hennekens C Rosner B Speizer FE The use of estrogens and progestins and the risk of breast cancer in postmenopausal women N Engl J Med 1995, 332:1589-1593. 10.1056/NEJM199506153322401 7753136
5. Glass AG Hoover RN Rising incidence of breast cancer: Relationship to stage and receptor status J Natl Cancer Inst 1990, 82:693-696. 10.1093/ jnci/82.8.693 2319611
6. Ross RK Paganini-Hill A Wan P Pike M Effect of hormone replacement therapy on breast cancer: Estrogen versus estrogen plus progestin J Natl Cancer Inst 2000, 92:328-332. 10.1093/jnci/92.4.328 10675382
7. Schairer C Lubin J Troisi R Sturgeon S Brinton LA Hoover R Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk JAMA 2000, 283:485-491. 10.1001/jama.283.4.485 10659874
8. Willett WC Colditz G Stampfer M Postmenopausal estrogens: Opposed, unopposed, or none of the above JAMA 2000, 283:534-535. 10.1001/ jama.283.4.534 10659883
9. Li CI Weiss NS Stanford JL Daling JR Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-aged women Cancer 2000, 88:2570-2577. 10.1002/ 1097-0142(20000601)88:11<2570::AID-CNCR20>3.0.CO;2-O 10861435
10. Li CI Anderson BO Daling JR Moe RE Trends in incidence rates of invasive lobular and ductal breast carcinoma JAMA 2003, 289:1421-1424. 10.1001/ jama.289.11.1421 12636465
11. Rossouw JE Anderson GL Prentice RL LaCroix AZ Kooperberg C Stefanick ML Jackson RD Beresford SA Howard BV Johnson KC Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the Women's Health Initiative randomized controlled trial JAMA 2002, 288:321-333. 10.1001/jama.288.3.321 12117397
12. Hulley S Grady D Bush T Furberg C Herrington D Riggs B Vit-tinghoff E Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/ progestin Replacement Study (HERS) Research Group JAMA 1998, 280:605-613. 10.1001/jama.280.7.605 9718051
13. Haas JS Kaplan CP Gerstenberger EP Kerlikowske K Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results Ann Intern Med 2004, 140:184-188. 14757616
14. Grady D Herrington D Bittner V Blumenthal R Davidson M Hlatky M Hsia J Hulley S Herd A Khan S Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERSII) JAMA 2002, 288:49-57. 10.1001/jama.288.1.49 12090862
15. Clarke CA Purdie DM Glaser SL Population attributable risk of breast cancer in white women associated with immediately modifiable risk factors BMC Cancer 2006, 6:170. 1564035 16803628 10.1186/1471-2407-6-170
16. Beral V Breast cancer and hormone-replacement therapy in the Million Women Study Lancet 2003, 362:419-427. 10.1016/S0140-6736(03)14596-5 12927427
17. Ravdin PM Cronin KA Howlader N Berg CD Chlebowski RT Feuer EJ Edwards BK Berry DA The decrease in breast-cancer incidence in 2003 in the United States N Engl J Med 2007, 356:1670-1674. 10.1056/NEJMsr070105 17442911
18. Clarke CA Glaser SL Uratsu CS Selby JV Kushi LH Herrinton LJ Recent declines in hormone therapy utilization and breast cancer incidence: clinical and population-based evidence J Clin Oncol 2006, 24:e49-e50. 10.1200/JCO.2006.08.6504 17114650
19. Robbins A Clarke C Regional changes in hormone therapy use and breast cancer incidence, California, 2001-2004 J Clin Oncol 2007. 17592152
20. Johnston M Breast cancer drop linked to fall in use of HRT New Zealand Herald http://www.nzherald.co.nz/section/ story.cfm?c_id=204&objectid=10416198 2006, 20 December
21. Katalinic A Rawal R Decline in breast cancer incidence after decrease in utilisation of hormone replacement therapy Breast Cancer Res Treat 2007. 17453336
22. Chen WY Hankinson SE Rosner B Colditz GA Past use of hormone replacement therapy and breast cancer risk [abstract 10518] J Clin Oncol 2007, Suppl:18S.